Xiangju Kong

16.8k citations

20 papers · 5.1k indexed · 6 hit papers · h-index 16

Molecular Biology top 1%
Oncology top 0.5%
Computational Theory and Mathematics top 0.5%
Immunology top 5%
Pathology and Forensic Medicine top 2%

Co-authors: Roger S. Lo Antoni Ribas Hubing Shi Jeffrey A. Sosman Richard C. Koya Thinle Chodon Gatien Moriceau Mi‐Kyung Lee
Topics: Melanoma and MAPK Pathways (15 papers)Computational Drug Discovery Methods (5 papers)HER2/EGFR in Cancer Research (4 papers)
Cited by: Oncology Molecular Biology Computational Theory and Mathematics
Journals: Nature Cell Angewandte Chemie International Edition
Partner nations: United States Australia China

In The Last Decade

Xiangju Kong

19 papers receiving 5.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

2010 1.6k citations Ramin Nazarian, Hubing Shi et al. Nature profile →
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

2013 715 citations Hubing Shi, Willy Hugo et al. Cancer Discovery profile →
Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance

2012 470 citations Hubing Shi, Gatien Moriceau et al. Nature Communications profile →
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma

2014 427 citations Judith M. Müller, Oscar Krijgsman et al. Nature Communications profile →
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

2015 412 citations Willy Hugo, Hubing Shi et al. Cell profile →
Therapy-induced tumour secretomes promote resistance and tumour progression

2015 364 citations Anna C. Obenauf, Yilong Zou et al. Nature profile →

Peers

Countries citing papers authored by Xiangju Kong

Since Specialization

Citations

This map shows the geographic impact of Xiangju Kong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiangju Kong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiangju Kong more than expected).

Fields of papers citing papers by Xiangju Kong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiangju Kong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiangju Kong. The network helps show where Xiangju Kong may publish in the future.

Co-authorship network of co-authors of Xiangju Kong

This figure shows the co-authorship network connecting the top 25 collaborators of Xiangju Kong. A scholar is included among the top collaborators of Xiangju Kong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiangju Kong. Xiangju Kong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Flow-Sediment Interaction and Formation Mechanism of Sediment Longitudinal Streaky Structures in Rough Channel Flows 2024 ·Journal of Hydraulic Engineering ·(unknown),Xiangju Kong,Qiang Zhong,Feng Yang,(unknown),Wei Wu	1
2	Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation 2017 ·Cancer Discovery ·Chunying Song,Marco Piva,Lu Sun,Aayoung Hong,Gatien Moriceau,Xiangju Kong,Hong Zhang,Shirley H. Lomeli,Jin Qian,Clarissa C. Yu,Robert Damoiseaux,Mark C. Kelley,(unknown),Philip O. Scumpia,Jeffrey A. Sosman,Douglas B. Johnson,Antoni Ribas,Willy Hugo,Roger S. Lo	109
3	JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma 2016 ·Cell Discovery ·Bjoern Titz,Anastasia Lomova,(unknown),Willy Hugo,Xiangju Kong,Johanna ten Hoeve,Michael Friedman,Hubing Shi,Gatien Moriceau,Chunying Song,Aayoung Hong,Mohammad Atefi,Richard Li,Evangelia Komisopoulou,Antoni Ribas,Roger S. Lo,Thomas G. Graeber	43
4	Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction 2015 ·Cancer Cell ·Gatien Moriceau,Willy Hugo,Aayoung Hong,Hubing Shi,Xiangju Kong,Clarissa C. Yu,Richard C. Koya,Ahmed A. Samatar,Négar Khanlou,Jonathan Braun,Kathleen Ruchalski,Heike Seifert,James Larkin,Kimberly B. Dahlman,Douglas B. Johnson,Alain P. Algazi,Jeffrey A. Sosman,Antoni Ribas,Roger S. Lo	237
5	Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistancebreakdown → 2015 ·Cell ·Willy Hugo,Hubing Shi,Lu Sun,Marco Piva,Chunying Song,Xiangju Kong,Gatien Moriceau,Aayoung Hong,Kimberly B. Dahlman,Douglas B. Johnson,Jeffrey A. Sosman,Antoni Ribas,Roger S. Lo	412
6	Therapy-induced tumour secretomes promote resistance and tumour progressionbreakdown → 2015 ·Nature ·Anna C. Obenauf,Yilong Zou,Andrew L. Ji,Sakari Vanharanta,Weiping Shu,Hubing Shi,Xiangju Kong,Marcus Bosenberg,Thomas Wiesner,Neal Rosen,Roger S. Lo,Joan Massagué	364
7	BRAF inhibitor acquired resistance: A multicenter meta-analysis of the spectrum and clinical implications of resistance mechanisms. 2015 ·Journal of Clinical Oncology ·Douglas B. Johnson,Alexander M. Menzies,Lisa Zimmer,Zeynep Eroglu,Fei Ye,Shilin Zhao,Antje Sucker,Helen Rizos,Willy Hugo,Ralf Gutzmer,Richard Kefford,Helen Gogas,Xiangju Kong,Richard A. Scolyer,Levi A. Garraway,Jeffrey A. Sosman,Antoni Ribas,Roger S. Lo,Georgina V. Long,Dirk Schadendorf	2
8	Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanomabreakdown → 2014 ·Nature Communications ·Judith M. Müller,Oscar Krijgsman,Jennifer Tsoi,Lídia Robert,Willy Hugo,Chunying Song,Xiangju Kong,Patrícia A. Possik,Paulien Cornelissen‐Steijger,Marnix H. Geukes Foppen,Kristel Kemper,Colin R. Goding,Ultan McDermott,Christian U. Blank,John B.A.G. Haanen,Thomas G. Graeber,Antoni Ribas,Roger S. Lo,Daniel S. Peeper	427
9	Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors 2014 ·Nature Communications ·Anna A. Marusiak,(unknown),Willy Hugo,Eleanor W. Trotter,María Romina Girotti,Natalie L. Stephenson,Xiangju Kong,Michael G. Gartside,Shameem Fawdar,Andrew Hudson,Wolfgang Breitwieser,Nicholas K. Hayward,Richard Marais,Roger S. Lo,John Brognard	63
10	Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapybreakdown → 2013 ·Cancer Discovery ·Hubing Shi,Willy Hugo,Xiangju Kong,Aayoung Hong,Richard C. Koya,Gatien Moriceau,Thinle Chodon,Rongqing Guo,Douglas B. Johnson,Kimberly B. Dahlman,Mark C. Kelley,Richard Kefford,Bartosz Chmielowski,John A. Glaspy,Jeffrey A. Sosman,Nicolas van Baren,Georgina V. Long,Antoni Ribas,Roger S. Lo	715
11	A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition 2013 ·Cancer Discovery ·Hubing Shi,Aayoung Hong,Xiangju Kong,Richard C. Koya,Chunying Song,Gatien Moriceau,Willy Hugo,Clarissa C. Yu,Charles Ng,Thinle Chodon,Richard A. Scolyer,Richard Kefford,Antoni Ribas,Georgina V. Long,Roger S. Lo	133
12	Polymer Nanofiber‐Embedded Microchips for Detection, Isolation, and Molecular Analysis of Single Circulating Melanoma Cells 2013 ·Angewandte Chemie International Edition ·Shuang Hou,Libo Zhao,Qinglin Shen,Juehua Yu,Charles Wang Wai Ng,Xiangju Kong,Dongxia Wu,Min Song,(unknown),Xiaochun Xu,Wei‐Han OuYang,(unknown),Xingzhong Zhao,Tom Lee,F. Charles Brunicardi,Mitch A. Garcia,Antoni Ribas,Roger S. Lo,Hsian‐Rong Tseng	182
13	Polymer Nanofiber‐Embedded Microchips for Detection, Isolation, and Molecular Analysis of Single Circulating Melanoma Cells 2013 ·Angewandte Chemie ·Shuang Hou,Libo Zhao,Qinglin Shen,Juehua Yu,(unknown),Xiangju Kong,Dongxia Wu,Min Song,Xiaohong Shi,Xiaochun Xu,Wei‐Han OuYang,(unknown),Xingzhong Zhao,Tom Lee,F. Charles Brunicardi,Mitch A. Garcia,Antoni Ribas,Roger S. Lo,Hsian‐Rong Tseng	21
14	Preexisting MEK1 Exon 3 Mutations in V600E/K BRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors 2012 ·Cancer Discovery ·Hubing Shi,Gatien Moriceau,Xiangju Kong,Richard C. Koya,Ramin Nazarian,Gulietta M. Pupo,Antonella Bacchiocchi,Kimberly B. Dahlman,Bartosz Chmielowski,Jeffrey A. Sosman,Ruth Halaban,Richard Kefford,Georgina V. Long,Antoni Ribas,Roger S. Lo	75
15	Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistancebreakdown → 2012 ·Nature Communications ·Hubing Shi,Gatien Moriceau,Xiangju Kong,Mi‐Kyung Lee,Hane Lee,Richard C. Koya,Charles Ng,Thinle Chodon,Richard A. Scolyer,Kimberly B. Dahlman,Jeffrey A. Sosman,Richard Kefford,Georgina V. Long,Stanley F. Nelson,Antoni Ribas,Roger S. Lo	470
16	Combinatorial Treatments That Overcome PDGFRβ-Driven Resistance of Melanoma Cells to V600EB-RAF Inhibition 2011 ·Cancer Research ·Hubing Shi,Xiangju Kong,Antoni Ribas,Roger S. Lo	184
17	Abstract 714: A potential epigenetic regulation of PDGFRβ overexpression in melanomas acquiring resistance to PLX4032 2011 ·Cancer Research ·Ramin Nazarian,Roberto Ferrari,Xiangju Kong,Siavash K. Kurdistani,Roger S. Lo	1
18	Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationbreakdown → 2010 ·Nature ·Ramin Nazarian,Hubing Shi,Qi Wang,Xiangju Kong,Richard C. Koya,Hane Lee,Zugen Chen,Mi‐Kyung Lee,Narsis Attar,Hooman Sazegar,Thinle Chodon,Stanley F. Nelson,Grant A. McArthur,Jeffrey A. Sosman,Antoni Ribas,Roger S. Lo	1614
19	Overexpression and characterization of a lipase from Bacillus subtilis 2005 ·Protein Expression and Purification ·(unknown),Zuoming Zhang,(unknown),Xiangju Kong,Yuguo Wang,Shugui Cao,Yan Feng	84
20	[Characteristics and application of thermophilic enzymes]. 2002 ·PubMed ·(unknown),(unknown),Shiyu Wang,Xiangju Kong,Shugui Cao	0

About Xiangju Kong

Xiangju Kong is a scholar working on Oncology, Computational Theory and Mathematics and Molecular Biology, having authored 20 papers that have together received 5.1k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (15 papers), Computational Drug Discovery Methods (5 papers) and HER2/EGFR in Cancer Research (4 papers). The work is most often cited by research in Oncology (2.7k citations), Molecular Biology (4.1k citations) and Computational Theory and Mathematics (779 citations). Xiangju Kong has collaborated with scholars based in United States, Australia and China. Frequent co-authors include Roger S. Lo, Antoni Ribas, Hubing Shi, Jeffrey A. Sosman, Richard C. Koya, Thinle Chodon, Gatien Moriceau, Mi‐Kyung Lee, Hane Lee and Stanley F. Nelson. Their work appears in journals such as Nature, Cell and Angewandte Chemie International Edition.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact